Addendum
Nivolumab (oesophageal cancer) - Addendum to Commission A20-121
Report documents
-
Addendum
Nivolumab (oesophageal cancer) - Addendum to Commission A20-121
Dossier assessment
Indication:
Adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (after prior fluoropyrimidine- and platinum-based combination chemotherapy)
Result of dossier assessment:
added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021.07.01 A G-BA decision was published.
Project details
- Project no.
- A21-62
- Commission
- Commission awarded on 11.05.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed